Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...
Investor's Business Daily on MSN10h
Airbnb Stock Jumps As Sales Growth Accelerates, Guidance Eases Concerns
Airbnb Eases Margin Concerns. While Airbnb's sales guidance for the current quarter was slightly below estimates, Wedbush ...
Investor's Business Daily on MSN11h
Dexcom Stock Makes A Recovery After Its Fourth-Quarter Fumble
Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.
Equal-weight S&P 500 clings to gain as these sectors trade in the green
A gauge of the U.S. equities that equally weights stocks in the S&P 500 index was clinging to a slight gain on Friday afternoon. The Invesco S&P 500 Equal Weight ETF was up 0.1% in afternoon trading, ...
DaVita's stock leads S&P 500 decliners after Berkshire pares stake. Its soft guidance isn't helping.
DaVita Inc.'s stock was tumbling 13.5% Friday to lead S&P 500 decliners, after Warren Buffett's Berkshire Hathaway Inc. pared its stake in the provider of kidney dialysis.
Can Lofty U.S. Stock Market Valuations Be Safely Ignored?
The persistent rise in US equities is helping promote a view that the relationships of old for stocks and traditional measures for value-oriented investing strategies no longer apply.